Table 7. Vaccine abbreviations and groupings used for annual report1.
| Targeted infections | Vaccines marketed in Canada trade name (MAH2) | Vaccine group abbreviation | % only vaccine given | 2012 AEFI | 2012 SAE (% AEFI) | Combined 2011−2012 AEFI reporting rate per 100,000 doses distributed |
|---|---|---|---|---|---|---|
| Vaccines used in publicly funded immunization programs | ||||||
| Diphtheria, Tetanus, Pertussis | Adacel® (SP) Boostrix™ (GSK) | Tdap | 67 | 334 | 3(0.9) | 20.0 |
| Diphtheria, Tetanus, Pertussis, Polio | Quadracel® (SP), Infanrix™-IPV (GSK) | DTaP-IPV | 53 | 176 | 6(3.4) | 101.0 |
| Adacel®-Polio (SP), Boostrix®-Polio (GSK) | Tdap-IPV | 57 | 60 | 1(1.7) | 15.2 | |
| Diphtheria, Tetanus, Pertussis, Polio, H. influenzae type b | Pediacel® (SP), Infanrix™-IPV/Hib (GSK), | DTaP-IPV-Hib | 42 | 498 | 38(7.6) | 37.6 |
| Diphtheria, Tetanus, Pertussis, Polio, H. influenzae type b, Hepatitis B | Infanrix hexa™ (GSK) | DTaP-HB-IPV-Hib | 16 | 214 | 12(5.6) | 148.2 |
| Diphtheria, Tetanus, Polio | Td Polio Adsorbed (SP) | Td-IPV | 47 | 15 | 1(6.7) | 22.1 |
| Diphtheria, Tetanus | Td Adsorbed (SP) | Td | 54 | 80 | 2(2.5) | 10.3 |
| Invasive pneumococcal disease | Prevnar® (Pfiz), Synflorix™ (GSK), Prevnar®13 (Pfiz) | Pneu-C | 6 | 682 | 78(11.4) | 56.8 |
| Pneumo® 23 (SP), Pneumovax® 23 (MF) | Pneu-P-23 | 50 | 228 | 18(7.9) | 38.0 | |
| Invasive meningococcal disease | Meningitec® (Pfiz), Menjugate® (NP), Neis Vac-C® (GSK) | Men-C-C | 6 | 468 | 61(13.0) | 85.2 |
| Menactra® (SP), Menveo™ (NVD), Nimenrix™ (GSK) |
Men-C-ACYW-135 | 48 | 84 | 2(2.4) | 23.7 | |
| Menomune® - A/C/Y/W-135 (SP) | Men-P-ACYW-135 | 0 | 2 | 0 | NC3 | |
| Hepatitis B | Engerix®-B (GSK), Recombivax HB® (MF) | HB | 38 | 213 | 11(5.2) | 22.0 |
| Hepatitis A, Hepatitis B | Twinrix® & Twinrix® Junior (both GSK) | HAHB | 56 | 90 | 3(3.3) | 10.1 |
| Hepatitis A | Avaxim® & Avaxim®-Pediatric (both SP), Havrix®1440 & Havrix®720Junior (both GSK), Vaqta® (MF) | HA | 24 | 70 | 2(2.9) | 14.1 |
| Hepatitis A, Typhoid | ViVAXIM™ (SP) | HA-Typh-I | 46 | 11 | 0 | 20.8 |
| Measles, Mumps, Rubella | M-M-R® II (MF), Priorix® (GSK) | MMR | 20 | 393 | 29(7.4) | 68.2 |
| Measles, Mumps, Rubella + Varicella | Priorix-Tetra™ (GSK) | MMRV | 17 | 163 | 42(25.8) | 53.7 |
| Varicella | Varilrix® (GSK), Varivax® III (MF) | Var | 22 | 358 | 16(4.5) | 74.0 |
| Influenza | Fluviral® (GSK), Vaxigrip® & Intanza™ (both SP), Agriflu® (NVD), Fluad® (NP), DInfluvac® (API) Flumist® (AZC) | Inf | 82 | 913 | 36(3.9) | 8.5 |
| Human Papillomavirus | Gardasil® (MF), Cervarix™ (GSK) | HPV | 65 | 185 | 9(4.9) | 29.8 |
| Rotavirus | Rotarix™ (GSK), RotaTeq® (MF) | Rota | 11 | 228 | 21(9.2) | 30.5 |
| Special use vaccines (publicly funded in selected situations) | ||||||
| Tuberculosis | BCG (SP) | BCG | 100 | 5 | 0 | NC3 |
| Rabies | Imovax® Rabies(SP), RabAvert® (NP) | Rab | 85 | 39 | 0 | 135.1 |
| Non-publicly funded vaccines | ||||||
| Herpes Zoster | Zostavax® (MF) | Zos | 91 | 80 | 2(2.5) | 27.7 |
| H. influenza type b | ACT-HIB® (SP), Hiberix® (GSK), Liquid PedvaxHib® (MF) | Hib | 6 | 16 | 3(18.8) | 63.8 |
| Polio | Imovax® Polio (SP) | IPV | 3 | 29 | 0 | 28.2 |
| Cholera | Dukoral® (CV) | Chol-Ecol-O | 77 | 26 | 1(3.8) | 10.5 |
| Japanese Encephalitis | IXIARO® (NP) | JE | 57 | 7 | 1(14.3) | NC3 |
| Tickborne Encephalitis | FSME-IMMUN™ (Bax) | TBE | 100 | 1 | 0 | NC3 |
| Typhoid | Typherix™ (GSK), Typhim Vi® (SP), Vivotif® (CV) | Typh-I/O | 42 | 43 | 1(2.3) | 18.4 |
| Yellow Fever | YF-Vax® (SP) | YF | 24 | 25 | 0 | 33.5 |
1 Note: only those vaccines marketed in Canada for which at least one AEFI report was received by April 30, 2013, for vaccines administered in 2012. 2 Market Authorization Holders, including: API—Abbott Laboratories Ltd.; AZC—AstraZeneca Canada Inc.; Bax—Baxter Corporation; CV—Crucell Vaccines Canada; GSK—GlaxoSmithKline Inc.; MF—Merck Canada Inc.; NP—Novartis Pharmaceuticals Canada Inc.; NVD— Novartis Vaccines and Diagnostics, Inc.; Pfiz—Pfizer Canada Inc.; SP—Sanofi Pasteur Ltd. 3 NC—not calculated because of small sample (<10 reports over two years)